The Caris Precision Oncology Alliance™ (POA) convenes the brightest minds in oncology, cancer care, clinical research, and drug development. The vision statement of the POA is to build the best-in-class collaborative research network focusing on precision oncology to identify predictive and prognostic markers that help in improving the outcomes and clinical care of patients with cancer. The POA aims to deliver molecular science solutions to promote clinical trials that cultivate combined clinical-genomic data and collaborative research to advance the science of cancer care. The alliance is comprised of a growing network of leading cancer centers from across the country that demonstrate a commitment to precision medicine and work collaboratively to:
It’s important for oncologists and patients to know that their data is available to them for analysis. Our database of clinical outcomes is populated with anonymized data from POA member institutions and from commercially available data. This continuous feedback loop between finding new biomarkers and interpreting their significance, provides insights for drug developers, which ultimately feeds back into our system and directly helps patients.
The Caris Precision Oncology Alliance™ is focused on collecting the latest scientific developments in genomics in order to help ensure the availability of individualized data to oncologists and patients and to further advance the integration of molecular profiling into all aspects of cancer care .”
Chadi Nabhan, MD, MBA, FACP
Chairman
Precision Oncology Alliance
In addition to creating a thought leadership network to develop best practices and guidelines for integrating molecular profiling into patient treatment management, POA members:
Executive Committee
The Caris Precision Oncology Alliance™ (POA) Executive Committee establishes appropriate molecular testing principles to serve as guidelines for the consistent application of tumor profiling across the oncology community. The Executive Committee facilitates collaborative research studies across the POA and coordinates outcome tracking initiatives to generate and document additional medical evidence for the appropriate use and impact of profiling. The Executive Committee of the POA serves as a resource to Caris leadership helping to drive research strategy and direction.
Chairman
Precision Oncology Alliance
Chief, Hematology and Oncology
Georgetown University
Associate Center
Director Translational Sciences
Karmanos Cancer Institute
Associate Director for Clinical Research
USC Norris Comprehensive Cancer Center
Professor of OB-GYN
Deputy Director
University of Cincinnati Cancer Institute
Associate Dean for Oncologic Sciences
Brown University
Associate Professor
University of Puerto Rico
Director
UT Health San Antonio
MD Anderson Center
Chief Medical Officer
Professor and Chair
Emory University
Director, Cancer Center
Associate Director, Basic Sciences
University of Arizona
POA Working Groups
The POA Working Groups identify leadership opportunities, author publications, and develop protocols.
April Salama, MD
Associate Professor of Medicine
Duke Cancer Institute
Premal Thaker, MD, MS
Professor of OB-GYN
Washington University
Trisha Wise-Draper, MD, PhD
Associate Professor of Medicine
University of Cincinnati
Andrew Evens, DO, MSc
Director, Lymphoma Program
Rutgers Cancer Institute
Heloisa Soares, MD, PhD
Assistant Professor
Huntsman Cancer Institute
Sonika Dahiya, MD
Professor, Pathology & Immunology
Washington University
Salma Jabbour, MD
Professor
RWJUH/Rutgers Cancer Institute
Wafik El-Deiry, MD, PhD, FACP
Associate Dean
Brown University
POA Pathology Group
Sonika Dahiya, MD
Professor, Pathology and Immunology
Washington University
Yihong Wang, MD, PhD
Associate Professor of Path. & Lab. Medicine
Brown University
Giselle Y. Lopez, MD, PhD
Assistant Professor, Pathology
Duke University
Thuy Phung, MD, PhD
Associate Professor of Pathology
University of South Alabama
Evgeny Yakirevich, MD
Professor, Path. & Lab. Medicine
Brown University
Sam Wei, MD, PhD
Associate Professor, Pathology
Fox Chase Cancer Center
Rouba Ali-Fehmi, MD
Professor
Karmanos Cancer Institute
Olga Weinberg, MD
Associate Professor, Pathlogy
UT Southwestern
Rebecca Chernock, MD
Associate Professor, Path & Immun.
Washington University
Kajsa Affolter, MD
Assistant Professor, Pathology
Huntsman Cancer Institute
Andrew E. Rosenberg, MD
Professor, Vice Chair, Director, Pathology
University of Miami
Sanja Dacic, MD, Phd
Professor of Pathology
University of Pittsburgh Medical Center
David Braxton, MD
Molecular Genetic Pathologist
Hoag
Radiation Oncology Group
Shane Stecklein, MD, Phd
Assistant Professor, Dept. of Medicine
University of Kansas
Tu Dan, PhD
Assistant Professor
UT Southwestern
Diane Ling, MD
Assistant Professor
USC
Sagar Patel, MD
Assistant Professor
Winship Cancer Institute
Teresa Meier, MD
Assistant Professor
University of Cincinnati
Sana Karam, MD, PhD
Associate Professor
University of Colorado
Nitin Ohri, MD, MS
Associate Professor
Montefiore
The Caris Precision Oncology Alliance™ consists of leading cancer centers around the world that are committed to precision medicine and work collaboratively to advance the delivery of molecular testing and establish standards of care for profiling solid tumors.
Every day, new discoveries confirm the increasing and important role biomarker analysis and tumor profiling have in personalized cancer care. We contribute to the body of research in oncology to advance the understanding of molecular science and further enable the delivery of precision medicine.